New Leukemia Protocol Matches Safety of Older Treatment Despite Design Changes
Swedish researchers found that a redesigned childhood leukemia treatment protocol produced similar toxicity levels to its predecessor, despite significant changes in drug combinations and dosing schedules. The finding matters to health systems and pharmaceutical developers: it suggests treatment modifications can reduce certain side effects without compromising overall safety, potentially lowering healthcare costs and improving patient quality of life during cancer therapy.
Originaltitel: Early Toxicity in Childhood Acute Lymphoblastic Leukemia: A Comparison of NOPHO ALL2008 and ALLTogether Protocols in Sweden
Background: The European ALLTogether protocol for childhood acute lymphoblastic leukemia, initiated in Sweden 2019, introduced earlier asparaginase during induction, dexamethasone instead of prednisone for all patients, and omitted anthracyclines from low-risk induction to reduce treatment-related toxicity. Consolidation-1 was based on the Induction 1B-phase developed by the BFM-group, replacing mercaptopurine, methotrexate, and asparaginase used in the previous NOPHO ALL2008 protocol, ALL2008. Following implementation, early treatment toxicity was considered unacceptably high, prompting a protocol amendment. We compared the prevalence of 14 predefined toxicities, the number of inpatient days, and weight changes during induction and consolidation-1 between the two protocols. Methods: We conducted a population-based cohort study in Sweden, reviewing patient records from 117 children treated under ALLTogether protocol and 234 matched controls under ALL2008 protocol. Results: The mean number of toxicities per patient was similar between the protocols (2.5 [290/117] vs. 2.3 [547/234]). ALLTogether cohort had significantly greater weight gain, with over 50% experiencing a > 10% increase (p < 0.01). Hyperglycemia (OR 5.17, 95% CI 1.93-13.82) and osteonecrosis (3.4% vs. 0%, p = 0.012) were more common, while liver dysfunction (0.59, 0.38-0.93) was less frequent in the ALLTogether protocol. The number of inpatient days was similar across protocols, except for the initial hospitalization, which was longer in ALLTogether (median 11 vs. 7 days, p < 0.01). Conclusions: The early introduction of asparaginase likely contributed to increased weight gain, hyperglycemia, and osteonecrosis. While overall toxicity burden remained similar between protocols, the shift in toxicity profile may explain the perception of increased early toxicity during treatment with the ALLTogether protocol.